Country: Unjoni Ewropea
Lingwa: Ingliż
Sors: EMA (European Medicines Agency)
autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human adenosine deaminase (ADA) cDNA sequence from human haematopoietic stem/progenitor (CD34+) cells
Fondazione Telethon ETS
L03
autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence
Immunostimulants,
Severe Combined Immunodeficiency
Strimvelis is indicated for the treatment of patients with severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), for whom no suitable human leukocyte antigen (HLA)-matched related stem cell donor is available (see section 4.2 and section 4.4).
Revision: 9
Authorised
2016-05-26
21 B. PACKAGE LEAFLET 22 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT OR CARER STRIMVELIS 1–10 × 10 6 CELLS/ML DISPERSION FOR INFUSION Autologous CD34 + enriched cell fraction that contains CD34 + cells transduced with retroviral vector that encodes for the human ADA cDNA sequence This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects your child may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOUR CHILD IS GIVEN THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOUR CHILD. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your child’s doctor or nurse. - If your child gets any side effects, talk to your child’s doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. - Your child’s doctor will give you a Patient Alert Card which contains important safety information about your child’s treatment with Strimvelis. Read it carefully and follow the instructions on it. - Carry the Patient Alert Card with you at all times and always show it to the doctor or nurse when your child sees them or if your child goes to hospital. WHAT IS IN THIS LEAFLET 1. What Strimvelis is and what it is used for 2. What you need to know before your child is given Strimvelis 3. How Strimvelis is given 4. Possible side effects 5. How to store Strimvelis 6. Contents of the pack and further information 1. WHAT STRIMVELIS IS AND WHAT IT IS USED FOR Strimvelis is a type of medicine called a GENE THERAPY . It is made specially for each patient. Strimvelis is used in children to treat a serious condition called ADA-SCID (a _denosine deaminase-severe _ _combined immune deficiency_ ). It is used when your child cannot receive a bone marrow transplant from a family donor because the match is not close enough. ADA-SCID occurs because of a faulty gene in the blood cells of your child’s i Aqra d-dokument sħiħ
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Strimvelis 1-10 x 10 6 cells/mL dispersion for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 2.1 GENERAL DESCRIPTION An autologous CD34 + enriched cell fraction that contains CD34 + cells transduced with retroviral vector that encodes for the human adenosine deaminase (ADA) cDNA sequence from human haematopoietic stem/progenitor (CD34 + ) cells. 2.2 QUALITATIVE AND QUANTITATIVE COMPOSITION The medicinal product is packaged in one or more infusion bags. Each patient-specific infusion bag of Strimvelis contains an autologous CD34 + enriched cell fraction that contains CD34 + cells transduced with retroviral vector that encodes for the human ADA cDNA sequence. The quantitative information regarding CD34 + cells/kg and total cells in the product is presented in the labelling for each batch. The concentration is 1-10 x 10 6 CD34 + cells/mL. Excipient with known effect This medicinal product contains 0.15 mmol sodium per mL. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Dispersion for infusion. A cloudy to clear, colourless to pink dispersion of cells. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Strimvelis is indicated for the treatment of patients with severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), for whom no suitable human leukocyte antigen (HLA)- matched related stem cell donor is available (see sections 4.2 and 4.4). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Strimvelis must be administered in a specialist transplant centre, by a physician with previous experience in the treatment and management of patients with ADA-SCID and in the use of autologous CD34 + _ex vivo_ gene therapy products. It should only be adm Aqra d-dokument sħiħ